22
Participants
Start Date
May 15, 2021
Primary Completion Date
December 20, 2022
Study Completion Date
December 20, 2022
dronedarone 400 mg Oral Tablet
"Dronedarone is an anti-arrhythmic drug with properties belonging to Vaughan-Williams class I-IV.~Participants will receive dronedarone 400 mg tablet, to be taken orally and twice daily for 52 weeks."
Placebo
Participants will receive a placebo tablet matching the physical appearance of dronedarone, to be taken orally and twice daily for 52 weeks.
Emory University, Atlanta
Tulane University School of Medicine, New Orleans
Baylor College of Medicine, Houston
University of Colorado Health Memorial, Colorado Springs
Collaborators (2)
University of Washington
OTHER
Marrek, INC
UNKNOWN
Sanofi
INDUSTRY
Preventice
INDUSTRY
Mckesson
UNKNOWN
Tulane University School of Medicine
OTHER